Literature DB >> 28710539

[Treatment outcomes of recurrent respiratory papillomatosis : Retrospective analysis of juvenile and adult cases. German version].

V-A Papaioannou1, A Lux2, S Voigt-Zimmermann3, C Arens3.   

Abstract

BACKGROUND: Recurrent respiratory papillomatosis (RRP) is a rare, chronic disease of viral etiology which is characterized by multiple, recurrent growth of papillomas in the aerodigestive tract.
MATERIALS AND METHODS: The surgical outcomes and the recurrence rates of 106 patients with RRP of the larynx were analyzed. The patients were treated at the University of Magdeburg between 1983 and 2014. The surgical outcomes of conventional and laser surgery regarding time to relapse and complications were compared. In addition, the influence of the quadrivalent vaccine Gardasil® on the disease was analyzed in 10 patients.
RESULTS: Children with RRP had a statistically significant greater number of surgeries throughout their lifetimes compared to adult patients. There were no differences between the adult (n = 79) and juvenile (n = 27) groups in the time to relapse and the number of surgeries/year. The time to relapse and number of procedures/year were not influenced by the various surgical methods. Complications after conventional and laser surgery were not statistically different between the two groups. Serious complications and the need for a tracheotomy were only reported after conventional surgery. In the 10 patients who were immunized with Gardasil®, a statistically significant lower number of surgeries/year after vaccination was achieved.
CONCLUSION: RRP is a rare disease. Treatment requires experience and may be very difficult. The analysis of the course of the disease has shown that the treatment of choice is surgical excision with the CO2 laser combined with the quadrivalent or polyvalent vaccine. Consequent vaccination of both boys and girls has the potential to reduce the occurrence of RRP.

Entities:  

Keywords:  Gardasil®; Human papillomaviruses; Microsurgery; Neoplasms, glandular and epithelial; Recurrent respiratory papillomatosis (RRP)

Mesh:

Substances:

Year:  2017        PMID: 28710539     DOI: 10.1007/s00106-017-0377-1

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  28 in total

1.  Cidofovir and the black box warning.

Authors:  Andrew F Inglis
Journal:  Ann Otol Rhinol Laryngol       Date:  2005-11       Impact factor: 1.547

2.  Radiofrequency ablation (coblation): a promising new technique for laryngeal papillomata.

Authors:  M S Timms; I A Bruce; N K Patel
Journal:  J Laryngol Otol       Date:  2006-10-02       Impact factor: 1.469

3.  The use of the quadrivalent human papillomavirus vaccine (gardasil) as adjuvant therapy in the treatment of recurrent respiratory papilloma.

Authors:  David L Young; Michael M Moore; Lucinda A Halstead
Journal:  J Voice       Date:  2015-01-22       Impact factor: 2.009

4.  The course of laryngeal papillomatosis treated by endolaryngeal microsurgery.

Authors:  V Uloza
Journal:  Eur Arch Otorhinolaryngol       Date:  2000-11       Impact factor: 2.503

5.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

Authors:  Suzanne M Garland; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Diane M Harper; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Marc Steben; Janine Bryan; Frank J Taddeo; Radha Railkar; Mark T Esser; Heather L Sings; Micki Nelson; John Boslego; Carlos Sattler; Eliav Barr; Laura A Koutsky
Journal:  N Engl J Med       Date:  2007-05-10       Impact factor: 91.245

6.  Safety of intralesional cidofovir in patients with recurrent respiratory papillomatosis: an international retrospective study on 635 RRP patients.

Authors:  R E A Tjon Pian Gi; T Ilmarinen; E R van den Heuvel; L M Aaltonen; J Andersen; J W Brunings; M Chirila; A Dietz; F Ferran Vilà; G Friedrich; H H W de Gier; W Golusinski; M Graupp; A Hantzakos; R Horcasitas; J Jackowska; J C Koelmel; G Lawson; F Lindner; M Remacle; C Sittel; V Weichbold; M Wierzbicka; F G Dikkers
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-02-03       Impact factor: 2.503

7.  Long-term results of surgical treatment for recurrent respiratory papillomatosis.

Authors:  Simon Florian Preuss; Jens Peter Klussmann; Markus Jungehulsing; Hans Edmund Eckel; Orlando Guntinas-Lichius; Michael Damm
Journal:  Acta Otolaryngol       Date:  2007-11       Impact factor: 1.494

8.  Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial.

Authors:  G B Healy; R D Gelber; A L Trowbridge; K M Grundfast; R J Ruben; K N Price
Journal:  N Engl J Med       Date:  1988-08-18       Impact factor: 91.245

9.  Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.

Authors:  Elmar A Joura; Suzanne M Garland; Jorma Paavonen; Daron G Ferris; Gonzalo Perez; Kevin A Ault; Warner K Huh; Heather L Sings; Margaret K James; Richard M Haupt
Journal:  BMJ       Date:  2012-03-27

10.  Risk Factors for Dysplasia in Recurrent Respiratory Papillomatosis in an Adult and Pediatric Population.

Authors:  Selmin Karatayli-Ozgursoy; Justin Avery Bishop; Alexander Hillel; Lee Akst; Simon R A Best
Journal:  Ann Otol Rhinol Laryngol       Date:  2015-10-08       Impact factor: 1.547

View more
  1 in total

Review 1.  An updated review of the epidemiological factors associated with recurrent respiratory papillomatosis.

Authors:  Alexandra Welschmeyer; Gerald S Berke
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-01-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.